Introduction
============

Schizophrenia is a highly heritable disorder, but even its genetic architecture still remains unclear \[[@B1]\]. In order to reveal the genetic involvement in the etiology, several research designs have been adopted. Linkage studies have not, however, found strongly linked loci \[[@B2]\]. Alternatively, many association studies of schizophrenia have been performed because genetic association methods are a more powerful means for finding genes that are expected to have a small effect on risk for the disorder. Although many positive results were reported, most are never replicated extensively. To overcome this state of uncertainty, Bertram et al. assembled the SZGene database to aggregate the evidence for those genetic polymorphisms with the best, most reliable evidence for association with schizophrenia \[[@B3],[@B4]\]. SZGene is characterized by the inclusion of all published case-control genetic association studies appearing in peer-reviewed journals, and each association is evaluated using a uniform method of meta-analysis. This inclusive and consistent database renders sometimes ambiguous or amorphous bodies of evidence concrete, and highlights some of the most promising avenues for continued research by schizophrenia geneticists. From this database, we picked the most reliably associated variants, and sought to determine if these variants would be associated with risk for schizophrenia in our own case-control sample of Japanese ancestry. Consistent with a common-disease/common-variant hypothesis of the disorder, we would not hypothesize that each variant identified in SZGene would be a necessary component of the risk profile for schizophrenia in our sample, so we evaluated the independent and joint effects of the top seven variants. The objectives of this study were: 1) to determine if the top candidate genes for schizophrenia would show replicated evidence for a contribution to risk for the disorder; and 2) to see if the aggregate effect of these seven top variants was stronger than the individual effects of each variant alone.

Methods
-------

Based on the information in SZGene as of February 2007, each positively associated genetic polymorphism in the database was ranked according to its p-value from a chi-square test of association with the disorder. The p-values of the seven top-ranked polymorphisms were all less than 0.005 (Table [1](#T1){ref-type="table"}). We chose these seven variants for the pragmatic reason of cost and effort. To evaluate these selected polymorphisms, we recruited 407 patients diagnosed with schizophrenia by multiple psychiatric doctors according to DSM-IV TR criteria and 384 normal controls without any medical record in psychiatry. Every participant gave written and oral informed consent, and this study was approved by the ethical committee at Osaka Medical College. The cases were recruited from inpatients in two mental hospitals and one university hospital located in the western area of Japan, and the controls were recruited among hospital staff. The details of the samples are described in the Table [2](#T2){ref-type="table"}. No statistical difference was observed in the male/female ratio of the participants, while the patients were significantly younger than the controls. All of the participants lived in the western area of Japan, and were self-reported ethnically Japanese.

###### 

Derived data from SZGene for investigated genes and polymorphisms

       Gene     Polymorphism     Denomination   p-value     OR            95%CI         Cases   Control                                     
  ---- -------- ---------------- -------------- ----------- ------------- ------------- ------- --------- ------ ------ ----- ------ ------ ------
  1    DRD2     rs6277(C/T)                     5.71.E-06   1.4           (1.2-1.63)    178     266       130    574    225   484    332    1041
                                                                                                                                            
  2    DRD2     rs1801028(G/C)   8.24.E-06      1.34        (1.11-1.61)   9             270     3770      4049   8      254   5420   5682   
                                                                                                                                            
  3    GRIN2B   rs1019385(T/G)   (200T/G)       4.70.E-05   0.69          (0.54-0.88)   85      256       161    502    114   257    95     466
                                                                                                                                            
  4    TPH1     rs1800532(A/C)   7.99.E-05      1.25        (1.08-1.44)   324           609     306       1239   344    851   513    1708   
                                                                                                                                            
  5    MTHFR    rs1801133(T/C)   (C677T)        2.15.E-04   1.14          (1.03-1.25)   490     1672      1708   3870   550   2265   2536   5351
                                                                                                                                            
  6    DTNBP1   rs2619528(A/G)   (P1765)        4.08.E-04   1.25          (1.01-1.56)   90      558       1049   1697   79    641    1485   2205
                                                                                                                                            
  7    DRD4     120-bpTR(S/L)                   3.80.E-03   0.81          (0.7-0.94)    55      374       807    1236   77    412    710    1199
                                                                                                                                            
  8    PLXNA2   rs1327175(G/C)   0.043          0.76        (0.58-0.99)   12            221     1478      1711   15     280   1475   1770   
                                                                                                                                            
  9    DAOA     rs3916971(T/C)   0.045          0.84        (0.73-0.96)   169           401     274       844    213    457   252    922    
                                                                                                                                            
  10   HP       HP1/2                           0.044       0.88          (0.8-0.98)    184     647       515    1346   324   995    699    2018

Abbreviation:

DRD2 = dopamine receptor D2, GRIN2B = glutamate receptor, ionotropic, N-methyl D-aspartate 2B, TPH1 = tryptophan hydroxylase 1, MTHFR = methylenetetrahydrofolate reductase, DTNBP1 = dystrobrevin binding protein 1, DRD4 = dopamine receptor D4, PLXNA2 = plexin A2, DAOA = D-amino acid oxidase activator, HP = haptoglobin

SCZ = Schizophrenia, NCs = Normal Controls, rs = Reference Single Nucleotide Polymorphism, bpTR = base pair Tandem Repeat, m = wild allele, M = mutant allele, S = Short allele, L = Long allele, SZGene = Schizophrenia Gene Database (<http://www.szgene.org/>), OR = Odds Ratio, CI = Confidential Interval

###### 

Demographic Samples

        Number   Male         Mean Age   PANSS Average   Paranoid form   Hebephrenic form   Catatonic form
  ----- -------- ------------ ---------- --------------- --------------- ------------------ ----------------
  SCZ   407      221(54.3%)   47.2       80.2            76.4%           13.5%              3.1%
                                                                                            
  NCs   384      194(50.5%)   42.1       \-              \-              \-                 \-

Abbreviation:

SCZ = Schizophrenia, NCs = Normal Controls, PANSS = Positive and Negative Syndrome Scale

With regard to the genotyping procedure, Single nucleotide polymorphisms (SNPs) on the genomic DNA extracted from venous blood were identified by FRET method (Roche Diagnostics, Japan) according to the manufacture\'s protocol. The 120 bp Tandem Repeat polymorphism in DRD4 was detected by restriction fragment length polymorphism. Each primer and probe was provided on demand.

In addition to the analysis of each single polymorphism, we sought to aggregate the vulnerability of the disorder based on the participants\' genetic information. The risk alleles of each of the seven top polymorphisms shown in SZGene were summated, such that an individual homozygous for a polymorphism\'s risk alleles was quantified as having a value of \"2\". The heterozygous genotype was given the value of \"1\", and the homozygote of non-risk alleles was coded \"0\". This scoring imparted an additive effect onto each variant, which was supported by the meta-analytic results in SZGene (although this may not be the true mode of inheritance of each gene\'s effect on risk, misspecification by an additive model is less costly than misspecification by other models). Each of the participants was additively scored from 0 to 14 according to their genetic vulnerability information from across all seven variants. This score was then entered as a predictor of case status in a logistic regression model, with the type-I-error rate fixed at 0.05.

Results
=======

The distribution of no single polymorphism was significantly different between schizophrenia and control groups at a p-value less than 0.05 (Fisher\'s exact test for each variant and t-test for aggregated seven variants, Table [3](#T3){ref-type="table"}). Moreover, no statistically significant deviation in the genetic vulnerability index derived from all seven variants was found within the seven top-ranked polymorphisms. In fact, the average risk-index score in the schizophrenia group (6.5 ± 1.57) was slightly lower than among controls (6.6 ± 1.39) (Figure [1](#F1){ref-type="fig"}). This is consistent with the negative results from the logistic regression analysis of the risk-index score, which found a non-significant (p = 0.783) and slightly negative (β = -0.02) effect of increments in the risk-index on likelihood of being in the schizophrenia group. Our failure to find a higher-order genetic effect of these seven variants on vulnerability to schizophrenia persisted when we reanalyzed the data after assigning a weight to each risk allele proportional to its odds ratio as indicated in SZGene. Again, a negative result was obtained when risk-allele carriers (risk-allele homozygotes and risk-allele heterozygotes) were pooled, suggesting that neither an additive nor a dominant model of the joint effects of these seven variants could be supported.

###### 

P-value for the Individual SNPs and the Aggregation of Seven Variants

  Gene     SNP         SCZ       NCs       Individual SNPs(Fisher\'s exact test)   Aggregation of Seven SNPs(t-test)                                                         
  -------- ----------- --------- --------- --------------------------------------- ----------------------------------- --------- --------- --------------------------------- ---------------------------------
                                                                                                                                           **p-value for Additive effect**   **p-value for Additive effect**
                                                                                                                                                                             
  DRD2     rs1801028   **C/C**   **C/G**   **G/G**                                 **C/C**                             **C/G**   **G/G**   0.275                             
                                                                                                                                                                             
                       390       14        8                                       354                                 23        7                                           
                                                                                                                                                                             
  DRD2     rs6277      **C/C**   **C/T**   **T/T**                                 **C/C**                             **C/T**   **T/T**   0.362                             
                                                                                                                                                                             
                       367       38        1                                       341                                 43        2                                           
                                                                                                                                                                             
  GRIN2B   rs101938    **T/T**   **T/G**   **G/G**                                 **T/T**                             **T/G**   **G/G**   0.67                              
                                                                                                                                                                             
                       91        206       110                                     81                                  204       100                                         
                                                                                                                                                                             
  TPH1     rs1800532   **A/A**   **A/C**   **C/C**                                 **A/A**                             **A/C**   **C/C**   0.635                             0.189
                                                                                                                                                                             
                       105       219       90                                      108                                 200       78                                          
                                                                                                                                                                             
  MTHFR    rs1801133   **T/T**   **T/C**   **C/C**                                 **T/T**                             **T/C**   **C/C**   0.519                             
                       69        184       160                                     64                                  183       138                                         
                                                                                                                                                                             
  DTNBP1   rs2619528   **G/G**   **G/A**   **A/A**                                 **G/G**                             **G/A**   **A/A**   0.193                             
                                                                                                                                                                             
                       326       77        4                                       323                                 60        1                                           
                                                                                                                                                                             
  DRD4     120bpTR     **S/S**   **S/L**   **S/L**                                 **S/S**                             **S/L**   **L/L**   0.095                             
                                                                                                                                                                             
                       24        138       248                                     16                                  158       211                                         

![**Numbers of the samples with each Risk-Index**. X-axis is \"Risk Index\", and Y-axis is the Numbers of the samples. The average and standard deviation of \"Risk Index\" for schizophrenia was 6.5 ± 1.57, while 6.6 ± 1.39 for normal controls. Abbreviation: SCZ = Schizophrenia, NCs = Normal Controls](1744-9081-7-43-1){#F1}

Discussion and Conclusion
=========================

In this study, we utilized the evidence from the SZGene database to build very strong hypotheses of independent and joint effects of the top seven most strongly supported risk genes for schizophrenia. These hypotheses were roundly unsupported. While our results alone are not enough to invalidate the conclusions gleaned from the large body of evidence collated in SZGene, they do cast doubt about the strength of the documented associations. Several potential confounders may be able to explain our results.

Chiefly, our failure to find significant associations could be a result of insufficient sample size and less-than-optimal statistical power. Our average power was 6.72% on the assessment of Genetic Power Calculator (type-I error rate at 0.05, and the prevalence of the disorder at 0.008, <http://pngu.mgh.harvard.edu/~purcell/gpc/>, Table [4](#T4){ref-type="table"}). This level of power is not enough to confidently refute the claims of significant association for these seven variants. The minor allele frequencies of some of these seven variants (in particular, rs1801028 on *DRD2*) are quite low (e.g., f = 0.05), which has adverse effects on the inferential power to detect the effects of those variants. Furthermore, this negative impact on power is likely to be compounded when investigating the joint effects of the seven SNPs. However, the direction of the effects identified in our sample was, for five of the variants (rs1801028 on *DRD2*, rs1019385 on *GRIN2B*, rs1800532 on *TPH1*, rs2619528 on *DTNBP1*, and rs1801133 on *MTHFR*), in the opposite direction of that documented in SZGene. Thus, even with the addition of more subjects, our sample likely would not yield any semblance of significant association for these five variants. For the remaining two variants (120bpTR on *DRD4*and rs6277 on *DRD2*) our detected effects were in the same direction as those reported in SZGene, suggesting that our data may in fact be consistent with the hypothesis of some effect of these variants on risk for the disorder in a global sense (though not necessarily a significant effect in our sample).

###### 

The deviation from Hardy-Weinberg Equilibrium (*X*^2^, more than 3.84 represents the significant deviation from HWE at 0.05 p-value) and genetic power for investigated samples (prevalence = 0.008, type II error = 0.80, general 2df, alpha = 0.05)

                       SCZ      NCs     Power
  -------- ----------- -------- ------- --------
  DRD2     rs1801028   0.67     4.16    0.0504
                                        
  DRD2     rs6277      109.57   46.21   0.0919
                                        
  GRIN2B   rs101938    0        0.26    0.0525
                                        
  TPH1     rs1800532   0.09     1.5     0.0806
                                        
  MTHFR    rs1801133   1.46     0.7     0.0563
                                        
  DTNBP1   rs2619528   1.66     0.06    0.069
                                        
  DRD4     120bpTR     0.05     1.07    0.0698

Another caveat in interpreting our results regards the analytic models we employed. In the present study, in order to reduce the complexity, it was simply hypothesized that the attributable odds ratio for each polymorphism was 2, and we hypothesized that vulnerability could be calculated additively (however, we also evaluated a dominant model with similar negative results). It could be suspected that the mode of inheritance of schizophrenia is not simply additive, however no definitive model is identified so far \[[@B1],[@B5],[@B6]\]. Re-analyses of these data with other modes of inheritance specified (e.g., recessive, multiplicative) may have yielded different results more consistent with expectations based on SZGene.

A third caveat regarding interpretation of our study is the ancestry of our sample. All of our subjects were derived from a sample of Asian ancestry, Japanese, although the top seven variants were selected based on their collective evidence from all ancestral groups (though SZGene represents more Caucasian samples than Asian ones). Given the possibility that the current lack of detection derived from this discrepancy, we recalculated the top variants in SZGene from samples of only Asian ancestry. Within the seven variants, the majority of variants (four out of seven) were still significant in the Asian-only subsamples, and the other three variants had only been examined in Asian-ancestry samples once or twice previously, precluding definitive answers. These data imply that the investigated variants were deserving of further research both in general and in Asian samples specifically. Nevertheless our currently employed samples will not generalize to all samples evaluated by the schizophrenia geneticists so far.

With regard to the deviation from Hardy-Weinberg Equilibrium (HWE), the current result of genotyping in cases for 120bp Tandem Repeat in DRD4, and both in cases and controls for rs1801028 in DRD2 has shown the deviation from HWE (Table [4](#T4){ref-type="table"}). Our finding on this article is not the simple positive association, therefore these deviations will not have a major influence on our overall conclusion. Although it is possible to expect that the deviated three group have false-negative association, we still conclude that our main finding will not be forced to change the fundamental direction.

Given these potential confounders it is keenly necessary to repeat this investigation in a larger, ethnically diverse population in order to validate (or invalidate) our model further. It is also important to aggregate the updated positive variants in the SZGene database when the replication work is conducted. Much work is needed in a collaborative effort in order to generate power to identify potential genetic markers for schizophrenia that transcend ethnicities and populations worldwide, if such exist. Studies of schizophrenia inevitably inherit the weaknesses of the current psychiatric nosology, which clinical observation (symptomatology) demands when we aimed to select the sample due to the lack of biological markers. Our current findings that there is no statistically significant deviation in the possession of \"risk-conferring\" alleles between schizophrenia and controls may have a chance to highlight the profound heterogeneity of the disorder of interest.
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